NBTXR3放射增强剂联合放疗对比单纯放疗治疗局部晚期软组织肉瘤的2-3期随机对照试验
Act.In.Sarc是一项2-3期随机对照试验,纳入180例局部晚期肢体或躯干壁软组织肉瘤患者,随机接受瘤内注射NBTXR3后术前放疗或单纯术前放疗。两组3-4级治疗出现的不良事件相似,最常见为术后伤口并发症(各9%)。
要点
- 两组3-4级术后伤口并发症发生率均为9%,安全性总体可控。
- NBTXR3相关最常见3-4级不良事件为低血压(7%)和注射部位疼痛(4%)。
核心结论
- NBTXR3联合术前放疗较单纯放疗显著提高局部晚期软组织肉瘤的病理完全缓解率。
- 该试验验证了放射增强剂的作用机制,可能拓展至其他癌症。
研究设计与样本
- Act.In.Sarc为2-3期随机、多中心、国际、开放标签试验。
- 纳入180例≥18岁局部晚期肢体或躯干壁软组织肉瘤患者,随机1:1接受NBTXR3+放疗或单纯放疗。
- 主要终点为意向治疗全分析集中经中心病理委员会评估的病理完全缓解比例。
主要发现
- 两组最常见的3-4级治疗出现不良事件均为术后伤口并发症(各8/89和8/90,9%)。
- NBTXR3相关3-4级不良事件:注射部位疼痛4/89(4%)、低血压4/89(4%);NBTXR3相关治疗出现3-4级低血压6/89(7%)。
- 放疗相关3-4级放射性皮肤损伤:NBTXR3组5/89(6%),单纯放疗组4/90(4%)。
- 严重不良事件:NBTXR3组35/89(39%),单纯放疗组27/90(30%);无治疗相关死亡。
关键数值与推荐
- 病理完全缓解定义依据欧洲癌症研究与治疗组织(EORTC)指南由中心病理委员会评估。
- 术前外照射放疗剂量为50 Gy分25次。
临床怎么用
- 对于需术前放疗的局部晚期肢体或躯干壁软组织肉瘤,可考虑联合NBTXR3以提高病理完全缓解率。
- 联合治疗时需监测低血压和注射部位疼痛等NBTXR3相关不良事件。
- 术后伤口并发症在两组中均常见,需加强围手术期伤口管理。
局限性
- 开放标签设计可能引入偏倚。
- 样本量有限,长期生存获益尚未报告。
- 研究仅纳入肢体或躯干壁软组织肉瘤,其他部位或亚型需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2-3 trial evaluated the safety and efficacy of the hafnium oxide (HfO2) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. METHODS: Act.In.Sarc is a phase 2-3 randomised, multicentre, international trial. Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included. Patients had to have a WHO performance status of 0-2 and a life expectancy of at least 6 months. Patients were randomly assigned (1:1) by an interactive web response system to receive either NBTXR3 (volume corresponding to 10% of baseline tumour volume at a fixed concentration of 53·3 g/L) as a single intratumoural administration before preoperative external-beam radiotherapy (50 Gy in 25 fractions) or radiotherapy alone, followed by surgery. Randomisation was stratified by histological subtype (myxoid liposarcoma vs others). This was an open-label study. The primary endpoint was the proportion of patients with a pathological complete response, assessed by a central pathology review board following European Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set. Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of radiotherapy. This study is registered with ClinicalTrials.gov, number NCT02379845, and is ongoing for long-term follow-up, but recruitment is complete. FINDINGS: Between March 3, 2015, and Nov 21, 2017, 180 eligible patients were enrolled and randomly assigned and 179 started treatment: 89 in the NBTXR3 plus radiotherapy group and 90 in the radiotherapy alone group. Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently discovered to be ineligible; thus, a total of 176 patients were analysed for the primary endpoint in the intention-to-treat full analysis set (87 in the NBTXR3 group and 89 in the radiotherapy alone group). A pathological complete response was noted in 14 (16%) of 87 patients in the NBTXR3 group and seven (8%) of 89 in the radiotherapy alone group (p=0·044). In both treatment groups, the most common grade 3-4 treatment-emergent adverse event was postoperative wound complication (eight [9%] of 89 patients in the NBTXR3 group and eight [9%] of 90 in the radiotherapy alone group). The most common grade 3-4 adverse events related to NBTXR3 administration were injection site pain (four [4%] of 89) and hypotension (four [4%]) and the most common grade 3-4 radiotherapy-related adverse event was radiation skin injury in both groups (five [6%] of 89 in the NBTXR3 group and four [4%] of 90 in the radiotherapy alone group). The most common treatment-emergent grade 3-4 adverse event related to NBTXR3 was hypotension (six [7%] of 89 patients). Serious adverse events were observed in 35 (39%) of 89 patients in the NBTXR3 group and 27 (30%) of 90 patients in the radiotherapy alone group. No treatment-related deaths occurred. INTERPRETATION: This trial validates the mode of action of this new class of radioenhancer, which potentially opens a large field of clinical applications in soft-tissue sarcoma and possibly other cancers. FUNDING: Nanobiotix SA.
引用
- Bonvalot S, Rutkowski PL, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019. PMID: 31296491. doi:10.1016/S1470-2045(19)30326-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。